Israel - English - Ministry of Health

inovamed ltd - vardenafil as hydrochloride trihydrate - film coated tablets - vardenafil as hydrochloride trihydrate 20 mg - vardenafil - treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for vardenafil inovamed to be effective, sexual stimulation is required. not indicated for use by women

Israel - English - Ministry of Health

inovamed ltd - vardenafil as hydrochloride trihydrate - film coated tablets - vardenafil as hydrochloride trihydrate 5 mg - vardenafil - treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. in order for vardenafil inovamed to be effective, sexual stimulation is required. not indicated for use by women

Israel - English - Ministry of Health

inovamed ltd - emtricitabine; tenofovir disoproxil as fumarate - film coated tablets - tenofovir disoproxil as fumarate 245 mg; emtricitabine 200 mg - tenofovir disoproxil and emtricitabine - tenovamed inovamed is indicated in combination with other anti-retroviral medicinal products for the treatment of hiv-1 infected adults over 18 years of age. tenovamed inovamed is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults at high risk

Israel - English - Ministry of Health

inovamed ltd - posaconazole - tablets delayed release - posaconazole 100 mg - posaconazole - posaconazole inovamed delayed-release tablets are indicated for use in the treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

Israel - English - Ministry of Health

inovamed ltd - tamsulosin hydrochloride - tablets prolonged release - tamsulosin hydrochloride 0.4 mg - tamsulosin - lower urinary tract symptoms ( luts) associated with benign prostatic hyperplasia (bph).

Israel - English - Ministry of Health

inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.

Israel - English - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 50 mg - bicalutamide - bicalutamide - for the treatment of advanced prostate cancer in combination with luteinising hormone-releasing hormone (lhrh) analog therapy or surgical castration.

Israel - English - Ministry of Health

inovamed ltd - bicalutamide - film coated tablets - bicalutamide 150 mg - bicalutamide - bicalutamide - in patients with locally advanced prostate cancer (t3 - t4 any n m0 t1 -t2 n+ m0), bicalutamide 150 mg is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable

Israel - English - Ministry of Health

inovamed ltd - anastrozole - film coated tablets - anastrozole 1 mg - anastrozole - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

Israel - English - Ministry of Health

inovamed ltd - exemestane 25 mg - film coated tablets - exemestane - exemestane inovamed is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. exemestane inovamed is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. exemestane inovamed is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.